Danaher reported on Thursday a 21 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. For the three months ended Dec. 31, conglomerate posted $8.15 billion in total sales compared to $6.76 billion in the year-ago period. The analysts' average estimate was $7.92 billion.

iHealth announced that it was disclosed in the previous announcement that the U.S. subsidiary of the company and the ACC of U.S. signed a purchase contract on ihealth coronavirus antigen home self-test OTC kit products on behalf of HHS, purchasing a total of 250 million iHealth kit products.

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant’s high rate of infection.

Ginkgo Bioworks said on Wednesday that it has acquired Project Beacon COVID-19, a Boston-based coronavirus testing organization.

ISB-led study shows unvaccinated pregnant people with COVID-19 are more likely to have poor birth outcomes even if they did not experience severe respiratory problems during infection.

On January 4th, the four-channel iPonatic nucleic acid detection analyzer of Sansure Biotech was certified by FDA. This is another global authority certification obtained after the approval of China NMPA and the European Union CE certification.

The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.

Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine.